Evercore ISI Group Downgrades Clovis Oncology to In-Line, Announces $8 Price Target

Evercore ISI Group downgrades Clovis Oncology (NASDAQ:CLVS) from Outperform to In-Line and announces $8 price target.

Benzinga · 11/19/2019 11:58

Evercore ISI Group downgrades Clovis Oncology (NASDAQ:CLVS) from Outperform to In-Line and announces $8 price target.